In addition, a high JAK2 V617F allele burden is a strong predictor of thrombosis and negative clinical outcomes,20 and these results suggest that reducing JAK2 V617F is important for preventing thrombosis, which is one of the treatment goals of PV. Here, JAK2 is linked to acquired polycythemia vera.